THE RED SECTION
costs and patterns of use for patients diagnosed with EoE have not been previously described. Th e aims of the present study were to estimate EoE-related health-care costs and utilization in the United States and to characterize the relative increase in costs and utilization for patients with EoE as compared with the general population.
Methods

Study design and data source
We performed a matched, case-control analysis using the IMS LifeLink PharMetrics Health Plan Claims Database (IMS Health Inc, Watertown, MA) to characterize health-care utilization and costs for EoE cases and controls. Th e database contains longitudinal, integrated, fully adjudicated medical and pharmaceutical claims for more than 75 million individuals from more than 80 health-care plans and has been shown to be representative of a US national commercially insured population ( 6, 7 ) . We analyzed data collected from 1 January 2009 through to 31 December 2010. We restricted the selection of cases and controls to those aged 0-64 years who were continuously enrolled throughout this time period and whose benefi t plan included prescription coverage.
Case and control selection
EoE cases were defi ned as patients with documentation of at least one instance of the ICD-9 code 530. 13 . We previously validated a single instance of this code for diagnosis of EoE by using health plan claims records among commercially insured patients ( 8 ) . Because we found that this case defi nition had high specifi city (>99%) but a low sensitivity (37%), we performed preplanned sensitivity analyses (see below). Controls were randomly selected from the enrollees meeting study inclusion criteria and were ageand sex-matched in a 4:1 ratio to EoE cases.
Statistical analysis
We estimated total, all-cause costs and claims for EoE patients both in sum and relative to controls. In this database, both charges and allowed costs are provided. For the purposes of this analysis, we used allowed costs, which represent the amount covered by the insurance provider plus the patient liability (e.g. co-pay, deductible, co-insurance).
We also characterized the costs and number of claims for EoE cases and controls for several types of services of interest. Specifically, we summed the total number of claims and costs (all-cause) for inpatient, outpatient, and emergency department services by patient and then obtained the mean and median claims and costs for service for cases and controls. We also calculated the total mean and median number of claims and costs for outpatient prescriptions and for upper endoscopies. Claims for upper endoscopies were identifi ed by Current Procedural Terminology (CPT) codes ( Supplementary Table 1 online). We also evaluated the costs and claims for EoE patients with and without concomitant allergic conditions as identifi ed from ICD-9 diagnostic codes ( Supplementary Table 1 ).
We assessed for statistically signifi cant diff erences in costs and claims for EoE patients vs. controls overall and by service type, and evaluated for diff erences by age and sex. We also calculated the diff erence in costs between the case and control groups to represent the health-care utilization attributable to EoE and conducted a sensitivity analysis for these total costs based on a range of possible prevalences. Details of the statistical analyses are described in the Supplementary Material .
Th is study was designated as exempt from review by the UNC Institutional Review Board.
RESULTS
A total of 8,135 cases of EoE and 32,540 sex-and age-matched controls met the inclusion criteria ( Table 1 ) . Th e mean age was 35.5±16.8 years; 21% were <18 years of age, and 65% were male. As expected with the matching strategy, cases and controls were identical in their distribution of age and sex. Relative to controls, a higher proportion of cases resided in the midwest region and a smaller proportion of cases resided in the east. A somewhat smaller proportion of cases had received insurance coverage through Medicaid (1.8 vs. 6.7%) ( Table 1 ).
Costs and claims attributable to EoE
For the 2-year period analyzed, all-cause total cost of health-care services and the total number of claims were signifi cantly higher 
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for EoE cases than for controls ( Table 2 ) . Th e median total cost was $6,608 for cases compared with $2,003 for controls ( P <0.001), and the median number of claims for cases was double that of controls (67 vs. 34; P <0.001). Th ese data are right-skewed because of small numbers of patients having signifi cantly higher claims and costs relative to most patients. However, the higher costs and number of claims associated with EoE was also observed when comparing means ( Table 2 ) . Stratifi cation of patients by age (<18 vs. 18-64) indicated that, for cases, the costs and number of claims were higher in the pediatric population ( Table 2 ) . Furthermore, we found that the relative diff erence in costs between cases and controls was signifi cantly higher for younger patients, and the diff erences were more pronounced for males. For costs for males, we found that for each 5-year increase in age there was a 12% decrease (95% CI: 13%, 11%) in costs for cases relative to controls. Among females, there was a 9% decrease (95% CI: 11%, 8%). Similarly, for total claims for males, for each 5-year increase in age there was a 17% decrease (95% CI: 19%, 15%) in the number of claims and for females there was a 13% decrease (95% CI: 16%, 11%). Moreover, relative to patients in the oldest age group, the diff erence between cases and controls was progressively greater as age decreased. Th is was true among both males and females ( Figure 1 ).
Th ere were 3,227 (39.7%) EoE cases with concomitant claims for an allergic condition. Th e median, all-cause total cost for cases with allergic disease was higher than that for those without allergic disease ($10,584 vs. $4,190; P <0.01). Similarly, the median number of claims was higher for EoE patients with allergic disease (106 vs. 43; P <0.01).
Inpatient, outpatient, and emergency room services
Evaluation of inpatient, outpatient, and emergency department services identifi ed similar patterns of higher costs and numbers of claims for EoE patients, although most subjects (EoE cases and controls) had no inpatient claims during the study period ( Table 3 ). Of note, the inpatient cost for pediatric controls was low, refl ecting that most children are healthy and do not require hospital admission.
For outpatient services, the number of claims and allowed costs were signifi cantly higher in EoE cases than in controls ( Table 4 ) . Th e diff erence between cases and controls was highest among children, where the median cost for cases was $6,327 vs. $752 for controls ( P <0.001). Similarly, the diff erence in the number of claims was highest among children.
Although few patients obtained emergency room department services in the 2-year study period, claims and costs were still significantly higher in EoE cases than in controls ( Supplementary Table 2 ).
Prescriptions
Th e median number of prescription claims was signifi cantly higher for EoE cases than for controls ( Supplementary Table 4 ) . Th e median allowed cost for outpatient prescriptions was generally about fourfold higher for EoE cases vs. controls overall ($650 vs. $151; P <0.001) and the diff erence persisted aft er stratifi cation by age ( Supplementary Table 4 ).
Upper endoscopies
Th e number of claims and costs for upper endoscopies was signifi cantly higher for EoE cases as compared with con- P for statistically signifi cant difference in median claims and median costs for each matched set-Wilcoxon signed rank test of the difference in the median of the sum of claims and costs for cases and the median of the sum of claims and costs for each matched set of controls. c All-cause expenses paid-including any subscriber-deductible and insurance provider payment for any claims.
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trols ( Supplementary Table 3 ). Th is yielded increased overall median cost for the EoE cases ($331 vs $0; P <0.001), and this diff erence persisted aft er stratifi cation by age ( Supplementary  Table 3 ).
Total burden of disease attributable to EoE
Th e annual, all-cause median cost per EoE patient was $3,304, and $1,001 for noncases. Th erefore, the EoE-attributable annual median cost for EoE patients is $2,302. On the basis of P for statistically signifi cant difference in median claims and median costs for each matched set-Wilcoxon signed rank test of the difference in the median of the sum of claims and costs for cases and the median of the sum of claims and costs for each matched set of controls. c All-cause expenses paid (US dollars) for claims made in an inpatient setting-including any subscriber-deductible and insurance provider payment for any claims.
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costs for EoE patients without allergic disease were still higher than for controls.
Putting these values into context illustrates that this is a remarkable level of expenditure for EoE. On the basis of a recent analysis of the burden of all GI illnesses, the costs attributable to EoE are roughly of the same order of magnitude as hospital-related costs for acute appendicitis ($1.4 billion), GI hemorrhage ($1.1 billion), Clostridium diffi cile infection ($1.1 billion), and infl ammatory bowel disease ($1 billion) ( 22 ) . Th e only cost data related to EoE of which we are aware were presented in abstract form and were derived from the Nationwide Inpatient Sample ( 23 ) . However, this study is not directly comparable to ours for several reasons: the data source was based on discrete hospitalizations, not longitudinal inpatient and outpatient records; the study population included only patients hospitalized for esophageal foreign body impactions; and the study analyzed hospital charges, not costs.
Th e high costs for patients with EoE refl ected in this analysis are consistent with the current management paradigm for EoE. For some patients, diagnosis and monitoring of the initial treatment course (oft en with expensive topical corticosteroids) will require three endoscopies over the course of 4-6 months ( 1 ) . In addition, EoE is primarily managed in the outpatient setting, explaining the low number of inpatient claims that we found. Th e higher costs in children are also understandable, as children undergoing endoscopy oft en require a hospital-based procedure unit and general anesthesia.
Th ere are some limitations in this study. First, because we used an administrative database, we had limited information pertaining previously described prevalence estimates ( 5 ) , we extrapolated total estimated costs for EoE in the United States. A lower-bound (56.7 cases/100,000) estimate of the total annual health-care cost related to EoE is $502,710,208 per year. Th e lower bound total excess cost for EoE patients is $350,329,980 per year. Extrapolating to the upper-bound estimate (153.2 cases/100,000), the total cost for EoE patients could be as high as $1,358,677,488 billion, with $946,633,044 million in excess of baseline cost.
Discussion
Over the past two decades, EoE has transformed from a casereportable disease to a major cause of upper GI morbidity ( 9-15 ) with an estimated prevalence of 0.5-1/1000 ( 5, (16) (17) (18) (19) (20) (21) . With EoE becoming more common, there is a pressing need to assess the disease burden of EoE as measured by health-care costs, claims, and utilization.
In this study, we used a large administrative database to estimate, for the fi rst time, the costs associated with having EoE. Th e results were striking, but not necessarily surprising. EoE diagnosis and treatment is expensive, and represents a substantial health-care burden. Depending on the prevalence estimate used, the total costs attributable to having a diagnostic code for EoE range from more than $500 million to more than $1.3 billion per year. Moreover, when the baseline costs from a control population are removed, approximately two-thirds of these costs remain directly attributable to EoE. Interestingly, costs and claims were higher for EoE patients with concomitant allergic diseases, but P for statistically signifi cant difference in median claims and median costs for each matched set-Wilcoxon signed rank test of the difference in the median of the sum of claims and costs for cases and the median of the sum of claims and costs for each matched set of controls. c All-cause expenses paid (US dollars) for claims made in an outpatient setting-including any subscriber-deductible and insurance provider payment for any claims.
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to certain demographic and clinical variables such as race, socioeconomic status, and practice setting. Second, misclassifi cation of disease status is possible. Administrative claims lack histologic data, and there are no diagnostic codes for proton pump inhibitorresponsive esophageal eosinophilia. If there were EoE cases who did not truly have EoE, their individual costs could either be higher or lower, depending on the condition that led them to seek treatment. However, we previously found that the ICD-9 code for EoE has a high specifi city but low sensitivity ( 8 ) , which would likely lead to underestimating the number of EoE cases and therefore lower cost estimates. Given the relative rarity of EoE, misclassifi cation of disease-free status among controls seems unlikely. Th ird, because of the database used, our cost estimates are restricted to those individuals aged 0-64 years with commercial insurance and prescription drug coverage, and are not necessarily generalizable to the under-or uninsured. However, the vast majority of EoE cases are in this age range. Th ere were also a higher proportion of controls with Medicaid as compared with cases. Although this could infl ate the costs for cases, it should not impact the number of claims. A sensitivity analysis restricting the case and control sample to subscribers with no Medicaid coverage did not materially change the results ($6,602 for cases vs $2,109 for controls; P <0.001). Finally, although comparison with controls provides an estimate of healthcare utilization associated with EoE, we cannot discern from these data whether the increase in cost for EoE patients with allergic disease represents costs attributable to the allergic disease itself, to varying treatment approaches for EoE patients with atopy (ie food elimination diets with expensive follow-up endoscopic monitoring), or to a more diffi cult-to-treat and costly phenotype of EoE. Despite these potential limitations, this is a very large claims database that has been demonstrated to be representative of all patients in the United States with commercial insurance, and allowed a comprehensive analysis of a large number of cases ( 6, 7 ) . We used actual costs, including allowed payouts by insurances and subscriber liability, instead of charges, and therefore our results closely refl ect true expenditures. We had the granularity to perform a detailed analysis of claims, sites of care, and pharmacy claims. Finally, we not only assessed the total costs related to EoE diagnostic codes but also calculated the costs directly attributable to EoE or EoE-related comorbidity by including matched control subjects in the analysis.
Our study design captured both incident and prevalent cases, which would include a proportion of patients who might have stable disease and require minimal ongoing evaluation. Th erefore, the utilization estimates presented in this study provide the bestknown estimate of the health-care burden for EoE disease given current standards for diagnosis and treatment. However, our study could not account for costs related to dietary therapy (either more expenses for hypoallergenic food products or for elemental formulas, neither of which are reimbursed by most insurers), for costs related to home health care, or for costs related to work absenteeism because of procedures or offi ce visits for either and their caretakers.
In conclusion, this matched, case-control analysis of a large administrative database found that EoE has an estimated annual health-care cost between $0.5 and $1.4 billion in the United States. Th is represents a remarkable burden of disease for an entity that was essentially unknown two decades ago. Th ese cost data refl ect current management strategies, which rely on upper endoscopy with biopsies for disease diagnosis and management. Th ese data can also be used by policy makers for planning and to inform resource allocation.
